TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18827210

Group type: EXPERIMENTAL
Intervention: 4-IM (intramuscular administration of AVA at 0, 2, and 4 weeks and 6 months; n = 165-170)
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: 3-IM (reduced 3-dose schedule of AVA; n = 501)
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: 4-SQ (subcutaneous administration of AVA at 0, 2, and 4 weeks and 6 months; n = 165-170)
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Control group (saline injections at the same time intervals; n = 169)
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: 4-IM vs 4-SQ
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Route of administration
Number of subjects: 1005
Study: 16313321

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 124

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cold ischemia time >14.5 h
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Recipient age
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 2-4 HLA-AB mismatches
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Donor age
Number of subjects: 124
Study: 11981349

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study: 10464886

Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler 400 micrograms once daily in the evening
Number of subjects: 181

Group type: COMPARATOR
Intervention: Budesonide Turbuhaler 200 micrograms twice daily
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler 200 micrograms once daily during the first open treatment period
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler 100 micrograms once daily during the second open treatment period
Number of subjects: 181
Study: 7818003

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional surgery (open surgery)
Number of subjects: 61
Study: 2169371

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (60 mg daily)
Number of subjects: 40
Study: 397800

Group type: EXPERIMENTAL
Intervention: Erythromycin stearate
Number of subjects: 21

Group type: COMPARATOR
Intervention: Erythromycin base
Number of subjects: 21
Study: 31142364

Group type: EXPERIMENTAL
Intervention: Comprehensive skin care and prevention strategy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard skin care
Number of subjects: 20
Study: 27770279

Group type: EXPERIMENTAL
Intervention: Bevacizumab + Temozolomide (TMZ) 75-100 mg/m2 day 1-21 of 28 day cycle
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Bevacizumab + Irinotecan (CPT) 125 mg/m2 every 2 weeks
Number of subjects: 117
Study: 25785807

Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity
Number of subjects: 471
Study: 24035872

Group type: EXPERIMENTAL
Intervention: Massage protocol (three sessions of 20 to 30 minutes on alternate days over a one-week period)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Massage session
Number of subjects: 52
Study: 21982956

Group type: EXPERIMENTAL
Intervention: APDDR-0901 (0.03% retinol, 0.7% rose extract, 0.05% hexamidine diisethionate)
Number of subjects: 97

Group type: COMPARATOR
Intervention: 0.1% adapalene gel
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: APDDR-0901
Number of subjects: 97
Study: 19132882

Group type: EXPERIMENTAL
Intervention: 30-minute exercise duration group
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 45-minute exercise duration group
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 16899841

Group type: EXPERIMENTAL
Intervention: Allergic rhinitis
Number of subjects: 2519

Group type: EXPERIMENTAL
Intervention: Sinusitis
Number of subjects: 2519
Study: 15564937

Group type: EXPERIMENTAL
Intervention: Down shoulder position
Number of subjects: 30

Group type: COMPARATOR
Intervention: Up shoulder position
Number of subjects: 30
Study: 11445771

Group type: EXPERIMENTAL
Intervention: Low volume familiarized eccentric exercise (LV+ECC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eccentric exercise (ECC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 0
Study: 9670867

Group type: EXPERIMENTAL
Intervention: Growth hormone and exercise intervention
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: IGF‐I levels treated as a continuous measure
Number of subjects: 155
Study: 7529680

Group type: EXPERIMENTAL
Intervention: 0.5 mg scopolamine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 3126956

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 302

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: beta blockers (prior treatment)
Number of subjects: 302
Study: 31256036

Group type: EXPERIMENTAL
Intervention: Daily oral insulin (7.5 mg for 2 months, 22.5 mg for 2 months, 67.5 mg until age 36.0 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily oral insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28291622

Group type: EXPERIMENTAL
Intervention: Combination therapy (ezetimibe 10mg/d and rosuvastatin 10mg/d)
Number of subjects: 125

Group type: COMPARATOR
Intervention: High-dose rosuvastatin (rosuvastatin 20mg/d)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Intermediate intensity rosuvastatin (rosuvastatin 10mg/d)
Number of subjects: 125
Study: 25735400

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 814

Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 814
Study: 23267856

Group type: EXPERIMENTAL
Intervention: GSK249320 (0.04, 0.4, 1.2, 3.5, 10, and 25 mg/kg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 22263329

Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride dentifrice (SnF2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 8.0% arginine-calcium carbonate-sodium monofluorophosphate dentifrice (positive control)
Number of subjects: 80
Study: 19930866

Group type: EXPERIMENTAL
Intervention: Ramipril (up to 10 mg/day)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Losartan (up to 100 mg/day)
Number of subjects: 53
Study: 16825591

Group type: EXPERIMENTAL
Intervention: SNP56
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: SNP42
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: SNP45
Number of subjects: 518
Study: 15021285

Group type: EXPERIMENTAL
Intervention: Intraoperative blood loss in the hematoma group (762 ± 735 mL; median 500 mL)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Intraoperative blood loss in the control group (415 ± 403 mL; median 300 mL)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Elevated intracranial pressure in the hematoma group (9/10 patients, 90%)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Elevated intracranial pressure in the control group (1/8 patients, 12.5%)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Clinical deterioration within 24 hours
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Clinical deterioration within 6 hours
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Clinical deterioration within 1 hour
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Decreased level of consciousness
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Increased focal neurologic signs
Number of subjects: 49
Study: 11227030

Group type: EXPERIMENTAL
Intervention: 0.9 g n-3 PUFA as fish oil
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 0.6 g n-3 PUFA as fish oil
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 0.3 g n-3 PUFA as fish oil
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 62
Study: 10023558

Group type: EXPERIMENTAL
Intervention: Tension-free hernioplasty (Lichtenstein, TAPP)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Shouldice technique
Number of subjects: 280
Study: 7869368

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 79

Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 79
Study: 3148139

Group type: EXPERIMENTAL
Intervention: 0.6 mg scopolamine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Concurrent articulation
Number of subjects: 20
Study: 31862185

Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen deprivation therapy (ADT)
Number of subjects: 8
Study: 29976358

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1905

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1905
Study: 27652718

Group type: EXPERIMENTAL
Intervention: LTHome
Number of subjects: 139

Group type: COMPARATOR
Intervention: EUT
Number of subjects: 139
Study: 25500337

Group type: EXPERIMENTAL
Intervention: 600 mg algal DHA supplementation (3 capsules per day)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo (mixed soy and corn oil)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: 600 mg algal DHA supplementation
Number of subjects: 205
Study: 23069814

Group type: EXPERIMENTAL
Intervention: Mechlorethamine, 0.02%, gel
Number of subjects: 260

Group type: COMPARATOR
Intervention: Mechlorethamine, 0.02%, compounded ointment
Number of subjects: 260
Study: 21911194

Group type: EXPERIMENTAL
Intervention: EasyTube (EzT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: esophageal-tracheal Combitube (ETC)
Number of subjects: 80
Study: 18218285

Group type: EXPERIMENTAL
Intervention: Fast-dissolving ibuprofen caplets
Number of subjects: 26

Group type: COMPARATOR
Intervention: Regular release ibuprofen caplets
Number of subjects: 26
Study: 11974477

Group type: EXPERIMENTAL
Intervention: Surgical intervention (not specified dosage or duration)
Number of subjects: 3756
Study: 9524895

Group type: EXPERIMENTAL
Intervention: Eltanolone
Number of subjects: 75

Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 75

Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 75
Study: 8077573

Group type: EXPERIMENTAL
Intervention: 90 mmol/L L‐glutamine added to standard WHO oral rehydration salts (WHO‐ORS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard WHO oral rehydration salts (WHO‐ORS)
Number of subjects: 120
Study: 2572120

Group type: EXPERIMENTAL
Intervention: Corticosteroid cream (clobetasol propionate)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo cream (base of the steroid cream)
Number of subjects: 11
Study: 796950

Group type: EXPERIMENTAL
Intervention: Ketoprofen (administered rectally at a dosage of 200 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28667222

Group type: EXPERIMENTAL
Intervention: PROPEL intervention (group exercise plus self-management)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control intervention (group aerobic exercise only)
Number of subjects: 192
Study: 26650153

Group type: EXPERIMENTAL
Intervention: Endobronchial valve treatment (EBV group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (standard medical care)
Number of subjects: 68
Study: 23908086

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg/d)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo (vitamin C)
Number of subjects: 121
Study: 21890003

Group type: EXPERIMENTAL
Intervention: Added external dead space (DS) 200 mL
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Added external dead space (DS) 400 mL
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control conditions (no added DS)
Number of subjects: 16
Study: 19515882

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting with coronary endarterectomy (Group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting without coronary endarterectomy (Group 2)
Number of subjects: 100
Study: 16423677

Group type: EXPERIMENTAL
Intervention: Mitral leaflet separation index
Number of subjects: 88

Group type: COMPARATOR
Intervention: Mitral valve area by planimetry
Number of subjects: 88

Group type: COMPARATOR
Intervention: Pressure half‐time
Number of subjects: 88
Study: 15013037

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg tablet daily for 5 days)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Co-amoxiclav (625 mg tablet every 8 hours for 7 days)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 162

Group type: COMPARATOR
Intervention: Co-amoxiclav
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Moxifloxacin and Co-amoxiclav
Number of subjects: 162
Study: 11697377

Group type: EXPERIMENTAL
Intervention: General request for data
Number of subjects: 29

Group type: COMPARATOR
Intervention: Specific request for data
Number of subjects: 29
Study: 9237640

Group type: EXPERIMENTAL
Intervention: Lovastatin (60 mg/day)
Number of subjects: 27
Study: 8217032

Group type: EXPERIMENTAL
Intervention: lovastatin 20 mg every day
Number of subjects: 293

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 293

Group type: COMPARATOR
Intervention: lisinopril
Number of subjects: 293

Group type: COMPARATOR
Intervention: nifedipine
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: lovastatin
Number of subjects: 293
Study: 31965873

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (home pharmacist visit, illustrated medication instructions, follow-up phone call)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 162
Study: 29384470

Group type: EXPERIMENTAL
Intervention: EVAR
Number of subjects: 626

Group type: COMPARATOR
Intervention: OR
Number of subjects: 626

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 626
Study: 27118453

Group type: EXPERIMENTAL
Intervention: Second-generation 8-color multiparameter-flow cytometry (MFC) for MRD monitoring
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: MRD negativity
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Immune profiling with MRD monitoring
Number of subjects: 162
Study: 25434315

Group type: EXPERIMENTAL
Intervention: Lamivudine (LAM)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Telbivudine (LDT)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Lamivudine and Adefovir dipivoxil (CLA) combination
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Patients with HBV DNA levels below quantitation limit (QL)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Patients with HBV DNA levels detectable but <10(4) copies/mL
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Patients with HBV DNA levels >10(4) copies/mL
Number of subjects: 164
Study: 22474997

Group type: EXPERIMENTAL
Intervention: Yougui Capsules at 1.68 g tid for 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Wuziyanzong Pills at 6 g bid for 12 weeks
Number of subjects: 80
Study: 20823406

Group type: EXPERIMENTAL
Intervention: Bortezomib plus dexamethasone
Number of subjects: 482

Group type: COMPARATOR
Intervention: VAD
Number of subjects: 482
Study: 18619828

Group type: EXPERIMENTAL
Intervention: O(2)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Air
Number of subjects: 25
Study: 16879073

Group type: EXPERIMENTAL
Intervention: ABL 735 blood gas analyzer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omni S blood gas analyzer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapidpoint 405 blood gas analyzer
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABL 620 blood gas analyzer (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparative analysis of new instruments against ABL 620
Number of subjects: 0
Study: 12830373

Group type: EXPERIMENTAL
Intervention: Retroperitoneal approach
Number of subjects: 23

Group type: COMPARATOR
Intervention: Transperitoneal approach
Number of subjects: 23
Study: 10606840

Group type: EXPERIMENTAL
Intervention: Midazolam (0.15 mg kg‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alpha-hydroxy-midazolam (0.15 mg kg‐1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 9148226

Group type: EXPERIMENTAL
Intervention: Torasemide (20 mg/die)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Furosemide (50 mg/die)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Torasemide (T)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Furosemide (F)
Number of subjects: 20
Study: 8211583

Group type: EXPERIMENTAL
Intervention: Glucan (beta 1-3 polyglucose)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 2946224

Group type: EXPERIMENTAL
Intervention: Etodolac 300 mg bid
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Etodolac 500 mg bid
Number of subjects: 23

Group type: COMPARATOR
Intervention: Piroxicam 20 mg qd
Number of subjects: 23
Study: 30637887

Group type: EXPERIMENTAL
Intervention: Full intervention (counseling session plus tailored brochure)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Generic information sheet
Number of subjects: 347

Group type: COMPARATOR
Intervention: Tailored brochure mailed after the ED visit
Number of subjects: 347

Group type: COMPARATOR
Intervention: Single motivational interviewing-based counseling session in the ED
Number of subjects: 347
Study: 30304118

Group type: EXPERIMENTAL
Intervention: Cognitive psychotherapy for depression
Number of subjects: 61
Study: 27115286

Group type: EXPERIMENTAL
Intervention: Multifaceted quality intervention (education, pathways, local champions, audit-feedback)
Number of subjects: 905
Study: 24823902

Group type: EXPERIMENTAL
Intervention: Standalone balloon dilation
Number of subjects: 92

Group type: COMPARATOR
Intervention: Functional endoscopic sinus surgery (FESS)
Number of subjects: 92
Study: 22703741

Group type: EXPERIMENTAL
Intervention: Core Conditioning exercises with the Stretch Pole (SP group)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Core Conditioning exercises without the Stretch Pole (C group)
Number of subjects: 14
Study: 20038911

Group type: EXPERIMENTAL
Intervention: Autologous bone
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Demineralized bone matrix
Number of subjects: 2

Group type: COMPARATOR
Intervention: Platelet-rich plasma
Number of subjects: 2

Group type: COMPARATOR
Intervention: Calcium hydroxyapatite
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (no graft)
Number of subjects: 2
Study: 18029292

Group type: EXPERIMENTAL
Intervention: Escitalopram (SSRI)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Optimised pharmacotherapy for CHF
Number of subjects: 700
Study: 16122909

Group type: EXPERIMENTAL
Intervention: Integrated treatment (IT)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Standard treatment (ST)
Number of subjects: 547
Study: 12009084

Group type: EXPERIMENTAL
Intervention: Leukocyte depletion by filtration with full-dose aprotinin
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard moderate hypothermic blood cardioplegia cardiopulmonary bypass
Number of subjects: 122
Study: 10412845

Group type: COMPARATOR
Intervention: Demineralized freeze dried bone allograft (DFDBA)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bovine derived xenograft (BDX) Bio-Oss
Number of subjects: 17
Study: 8520877

Group type: EXPERIMENTAL
Intervention: Granisetron + Dexamethasone
Number of subjects: 292

Group type: COMPARATOR
Intervention: Granisetron
Number of subjects: 292
Study: 2405343

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 25
Study: 7246035

Group type: EXPERIMENTAL
Intervention: Digitalis
Number of subjects: 20
Study: 29981250

Group type: EXPERIMENTAL
Intervention: Active expiratory muscle strength training (EMST)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham expiratory muscle strength training (EMST)
Number of subjects: 48
Study: 28495642

Group type: EXPERIMENTAL
Intervention: Lenalidomide therapy (initiated at 5 mg every other day, increased to 10 mg daily if tolerated)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard care (withdrawal of immunosuppression followed by donor lymphocyte infusion)
Number of subjects: 17
Study: 25577762

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective prediction-based treatment
Number of subjects: 0
Study: 23643110

Group type: EXPERIMENTAL
Intervention: Act in Case of Depression (AiD) implemented in somatic units
Number of subjects: 793

Group type: COMPARATOR
Intervention: Usual care (no intervention) in dementia units
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Adherence to depression assessment procedures
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Adherence to treatment pathways
Number of subjects: 793
Study: 21257003

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg/day
Number of subjects: 252
Study: 19415804

Group type: EXPERIMENTAL
Intervention: MAL 160 mg/g with 1 h incubation
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: MAL 160 mg/g with 3 h incubation
Number of subjects: 112

Group type: COMPARATOR
Intervention: MAL 80 mg/g
Number of subjects: 112
Study: 17895456

Group type: EXPERIMENTAL
Intervention: Telephonic outreach and care management program
Number of subjects: 604

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 604
Study: 12583920

Group type: EXPERIMENTAL
Intervention: Somatization Disorder (SD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abridged Somatization Disorder (ASD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multisomatoform Disorder (MSD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All three groups (SD, ASD, MSD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: General population
Number of subjects: 0
Study: 10708198

Group type: EXPERIMENTAL
Intervention: CCM elective intervention
Number of subjects: 40
Study: 9506002

Group type: EXPERIMENTAL
Intervention: Venlafaxine (50 mg every 8 hours for 7 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg on days 5 and 7)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8292113

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 475

Group type: COMPARATOR
Intervention: Allogeneic blood transfusion
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Blood transfusions (both types)
Number of subjects: 475
Study: 2428288

Group type: EXPERIMENTAL
Intervention: Sodium tetraborate
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Alum
Number of subjects: 26